Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.

In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.

A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.

Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.

As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.

Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.

India On Alert Against Polio

The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.

The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.

With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.

US researchers have identified the first known infection caused by Bourbon virus in a man from New York's Long Island, raising concerns that the rare tick-borne virus may have gone undetected for years.

The case, published in the American Journal of Tropical Medicine and Hygiene, suggests that the virus could be circulating more widely in the Long Island region than previously believed.

Because Bourbon virus causes symptoms similar to more common tick-borne illnesses, including Lyme disease, experts believe some infections may have been misdiagnosed.

What Is the Case?

In 2021, 67-year-old Michael Larkin was bitten by two lone star ticks while working outdoors. However, it took about 5 years to get a proper diagnosis.

Because his symptoms resembled those of more common tick-borne illnesses, including Lyme disease, doctors initially treated him with antibiotics. However, since antibiotics do not work against viral infections, his condition worsened and he developed fever, rash, night sweats and debilitating headaches.

The lack of a commercially available diagnostic test further complicated his diagnosis, making it difficult for physicians to identify the virus during the acute stage of illness.

Larkin's illness was confirmed to have been caused by Bourbon virus recently, after he got enrolled in a year-long antibody study, with blood samples collected every three months.

"Now we know the virus can be lethal. On Long Island, at least, we have a lot of lone star ticks," Dr. Luis Marcos, who treated Larkin, told CBS News. "And honestly this may be the very, very tip of the iceberg."

What Is Bourbon Virus?

Bourbon virus is a rare tick-borne virus believed to spread through the bite of infected lone star ticks (Amblyomma americanum).

According to the US Centers for Disease Control and Prevention (CDC), cases have previously been reported in parts of the Midwest, East Coast and Southern United States.

The virus was first identified in 2014 and was named after Bourbon County, Kansas, where it was initially discovered. There is currently no vaccine to prevent Bourbon virus infection and no specific antiviral treatment.

Symptoms of Bourbon Virus

People infected with Bourbon virus have reported symptoms including:

• Fever
• Fatigue
• Rash
• Headache
• Muscle and body aches
• Nausea and vomiting

• Low white blood cell counts
• Low platelet counts

How Does It Spread?

Bourbon virus is believed to spread through the bite of infected lone star ticks. These aggressive ticks are identified by the single white spot—or "lone star"—on the backs of adult females. They are commonly found in wooded areas, brush and tall grass.

Lone star ticks are also known to transmit several other diseases, including:

• Ehrlichiosis
• Tularemia
• Alpha-gal syndrome (red meat allergy)

Could More Cases Be Going Undetected?

The researchers noted that the Bourbon virus is likely more prevalent than we think in New York and other cases are likely not being diagnosed.

Marcos added that the findings highlight the urgent need for improved surveillance, expanded testing and better guidance for healthcare providers.

"Without identifying the cause of an infection, the chances of developing accurate diagnostic tests or effective treatments are minimal," Marcos said. "That is why it is so important to first understand the true impact of the virus in high-risk areas."

How to Prevent The Deadly Infection?

Health experts recommend taking the following precautions:

• Protect yourself from tick bites by avoiding wooded, brushy and grassy areas whenever possible.
• Stay in the center of hiking trails.
• Wear long sleeves and long pants outdoors.
• Treat clothing and gear with 0.5% permethrin.
• Use EPA-registered insect repellents containing ingredients such as DEET.
• Check your body, clothing and pets for ticks after spending time outdoors and remove attached ticks promptly.

Scientists have discovered an Achilles' heel that helps some of the most aggressive cancers escape treatment. The discovery that could pave the way for new targeted therapies against specific drug-resistant tumours.

Researchers at Nanyang Technological University (NTU) Singapore, identified a protein called TEX264 that enables cancer cells to escape the therapeutic effects of a widely used class of targeted cancer drugs known as PARP inhibitors. The study is published in Nature Cell Biology.

What Does This Mean For Drug-Resistant Cancers?

The findings could have positive implications for patients with triple-negative breast cancer, as well as ovarian, prostate, and pancreatic cancers that are treated with PARP inhibitors. These cancers eventually become resistant to the drugs.

"Our findings have identified a new biological process involving TEX264 as a key mechanism of drug resistance in an aggressive form of cancer," said Professor Kristijan Ramadan, who led the research. "We coined this new biological mechanism 'autophagy of DNA lesions', or simply 'nucleophagy'. This makes TEX264 a potential target for future cancer therapies."

Also read: Don't Fear The Biopsy, Fear The Delay

How Do Some Cancers Escape Treatment?

PARP inhibitors work by blocking PARP1, a protein that repairs damaged DNA inside cancer cells. Without this repair system, tumour cells accumulate DNA damage and die. However, many cancers eventually become resistant to this treatment.

The researchers discovered that TEX264 helps remove trapped PARP1 proteins from damaged DNA through a newly identified clean-up process called nucleophagy, allowing cancer cells to continue repairing themselves and escape the treatment. This is the cellular recycling system that makes cancer resistant to treatments.

When scientists blocked TEX264 in experiments, PARP1 remained stuck on DNA, DNA damage accumulated, and the cancer cells became far more vulnerable to therapy.

Also read: US FDA Approves New Blood Test To Screen For Colorectal Cancer

What Are PARP Inhibitors?

They are approved for several cancers, including ovarian, breast, prostate, and pancreatic cancer.

While many patients initially respond well, resistance develops in an estimated 40% to 70% of breast and ovarian cancer cases.

Also read: Scientists Find Rare Contagious Skin Cancer In Fish From US, Canada: Should Humans Worry?

Importance Of This Study

Instead of targeting the DNA repair machinery directly, the new study targets an entirely different weak spot, the cellular cycle that cancer cells exploit to discard damaged repair proteins.

Researchers believe drugs that inhibit TEX264 or block nucleophagy could potentially restore the effectiveness of existing PARP inhibitors, offering a new targeted treatment strategy for patients whose cancers no longer respond to therapy.

The researchers caution that the findings are currently based on laboratory studies, and more research, including clinical trials, will be needed before therapies targeting TEX264 can reach patients.

The promising results adds to growing efforts worldwide to overcome one of oncology's biggest challenges: preventing cancers from evolving resistance to life-saving treatments.

The World Health Organization (WHO) has updated its treatment guidelines for visceral leishmaniasis (VL), commonly known as kala-azar, and post-kala-azar dermal leishmaniasis (PKDL).

Through this update, WHO is recommending shorter, safer and more patient-friendly treatments that could improve outcomes for thousands of patients across eastern Africa and South-East Asia.

The revised guidance marks the first major update in nearly two decades for these forms of leishmaniasis.

It introduces new treatment options, including the use of oral miltefosine in combination therapies, reducing the need for long courses of painful daily injections.

What Is PKDL?

Post-kala-azar dermal leishmaniasis (PKDL) is a skin condition that appears months or years after a patient recovers from visceral leishmaniasis.

Visceral leishmaniasis, also known as kala-azar or black fever, is a life-threatening parasitic disease caused by Leishmania. It is spread by infected female sandflies. It attacks internal organs like the spleen and liver and is almost always fatal if left untreated.

In post-kala-azar, while patients usually feel well, they develop patches, papules or nodules on the skin that harbour the parasite. This allows sandflies to transmit the infection to others.

Early diagnosis and effective treatment of PKDL are therefore considered essential for interrupting transmission and elimination of kala-azar.

Also read: Uganda Declared Ebola-Free As Congo Outbreak Grows To 3,262 Cases, 1,437 Deaths

About The New Treatment Guidelines

WHO now recommends a 14-day regimen combining oral miltefosine with once-daily paromomycin injections for patients with primary visceral leishmaniasis in eastern Africa.

The new approach replaces older sodium stibogluconate-based regimens that required 17 days of treatment, 34 injections, which were often associated with toxicity.

The guidelines also introduce shorter treatment options for PKDL. For patients in eastern Africa and South-East Asia, WHO recommends new combination treatments that substantially shorten duration. It also allows part of the therapy to be completed at home.

Dr Daniel Ngamije Madandi, WHO Director of Malaria and Neglected Tropical Diseases, "For too long, patients suffering from leishmaniasis have endured treatments nearly as punishing as the disease itself. By recommending safer, shorter and more patient-friendly regimens, we are not just improving care; we are accelerating our fight to eliminate this devastating disease and offering renewed hope to communities across Africa and Asia."

Also read: Ebola Scare In The UK After Humanitarian Worker Monitored In London Hospital; Here's what Happened

Milestone In PKDL Treatment

The updated recommendations also revise the safety guidance for miltefosine in line with advice from the WHO Advisory Committee on the Safety of Medicinal Products and introduce allometric dosing to help optimise treatment across different body weights.

Kala-azar is one of the world's deadliest parasitic diseases after malaria. According to WHO, eastern Africa accounted for nearly 79% of global visceral leishmaniasis cases in 2024, with around half of patients being children under the age of 15.

Transmitted through the bite of infected female sandflies, it causes prolonged fever, weight loss, anaemia and enlargement of the spleen and liver. If left untreated, the disease is fatal in up to 95% of cases.